Difference between revisions of "Amatuximab (MORAb-009)"
Jump to navigation
Jump to search
m |
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
||
| Line 4: | Line 4: | ||
=Preliminary data= | =Preliminary data= | ||
==[[Mesothelioma]]== | ==[[Mesothelioma]]== | ||
| − | # Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36. Epub 2014 Sep 17. [ | + | # Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36. Epub 2014 Sep 17. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4252585/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25231400 PubMed] |
[[Category:Drug index]] | [[Category:Drug index]] | ||
Revision as of 02:36, 2 December 2016
Mechanism of action
Anti-mesothelin monoclonal antibody
Preliminary data
Mesothelioma
- Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36. Epub 2014 Sep 17. link to PMC article PubMed